



IMMUPARKNET

The role of IMMUnity in tackling PARKinson's disease through a Translational NETwork

IMMUPARKNET focuses on Parkinson's disease (PD) challenges and aims at establishing an innovative, multi-interdisciplinary Network

Why Parkinson's disease (PD) ?

Parkinson's disease (PD) is the 2nd most common neurodegenerative disorder worldwide, still **without cure**. Advances in knowledge and available treatments are thus urgently needed, and IMMUPARKNET aims to help on that: orchestrating a collaborative effort in optimising resources and supporting researchers via a common network

1.2M people with PD in Europe

What is IMMUPARKNET ?

IMMUPARKNET is an Action supported by the European Cooperation in Science and Technology (COST) funding organisation. IMMUPARKNET focuses on PD challenges and aims the establishment of an innovative, multi-interdisciplinary Research Network, fostering the exchange of expertise among outstanding experts from different countries and institutions



IMMUPARKNET aims



To foster fruitful exchanges of expertise among experts, involving researchers, clinicians, and students, bridging the outputs achieved with patients, their families and caregivers

This will allow a better sharing & development of research resources, straightening the road to **novel treatments**, the discovery of innovative drugs or pointing to **drug-repurposing** of existing ones, and, ultimately and hopefully, a **cure for the disease**

*Although widely recognised, the role of immunity in the onset and development of PD is still unclear. For this reason, one of our priorities is to **fill this knowledge gap** and devise standardised laboratory and therapeutic approaches, building on the latest advances of pre-clinical research*

IMMUPARKNET members

- Number of COST member countries: 20
- Number of ITC countries: 12
- Number of WG members: 79 (and growing!)



Want to get involved? JOIN US!

Find how to join our Action on <https://www.cost.eu/actions/CA21117/>